Summary Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now
a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer …

Small cell lung cancer (SCLC) tumors comprise heterogeneous mixtures of cell states,
categorized into neuroendocrine (NE) and non-neuroendocrine (non-NE) transcriptional …

Importance Patients with relapsed small cell lung cancer (SCLC), a high replication stress
tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor …

Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus
carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung …

Small cell lung cancer (SCLC) is an extremely aggressive neuroendocrine tumor,
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …

Neuroendocrine neoplasms (NENs) of the lung encompass neuroendocrine tumors (NETs)
composed of typical (TC) and atypical (AC) carcinoids and full-fledged carcinomas (NECs) …

Highlights•ICIs have shifted the treatment paradigm to improve overall survival in advanced
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …

SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC
initially responds very well to platinum-based chemotherapy, it eventually recurs and at …

The worldwide incidence of pulmonary carcinoids is increasing, but little is known about
their molecular characteristics. Through machine learning and multi-omics factor analysis …

Background Lineage plasticity, the ability to transdifferentiate among distinct phenotypic
identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs) …